NASDAQ: GALTGalectin Therapeutics Inc Stock
$1.38+0.01 (+0.73%)
Updated Apr 17, 2025
GALT Price
$1.38
Fair Value Price
N/A
Market Cap
$87.19M
52 Week Low
$0.73
52 Week High
$3.78
P/E
-1.82x
P/B
-0.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$47.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.15
Operating Cash Flow
-$42M
Beta
0.85
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GALT Overview
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GALT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GALT
Ranked#444 of 463
Ranked#444 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important GALT news, forecast changes, insider trades & much more!
GALT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GALT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GALT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
GALT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more GALT due diligence checks available for Premium users.
Valuation
GALT fair value
Fair Value of GALT stock based on Discounted Cash Flow (DCF)
Price
$1.38
Fair Value
-$0.77
Undervalued by
279.90%
GALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GALT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.82x
Industry
-177.72x
Market
27.98x
GALT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.83x
Industry
4.05x
GALT's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.0M
Profit Margin
0%
GALT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.5M
Liabilities
$120.6M
Debt to equity
-1.15
GALT's short-term liabilities ($35.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GALT's long-term liabilities ($85.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GALT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.8M
Investing
$0.0
Financing
$851.0k
GALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GALT vs Biotech Stocks
Galectin Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.